The estimated Net Worth of Colin John Meyer is at least $42.6 Million dollars as of 15 August 2023. Mr. Meyer owns over 2,740 units of Reata Pharmaceuticals Inc stock worth over $14,070,264 and over the last 8 years he sold RETA stock worth over $26,356,606. In addition, he makes $2,182,780 as Executive Vice President und Chief Research and Development Officer at Reata Pharmaceuticals Inc.
Colin has made over 10 trades of the Reata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,740 units of RETA stock worth $463,060 on 15 August 2023.
The largest trade he's ever made was selling 93,922 units of Reata Pharmaceuticals Inc stock on 2 March 2023 worth over $8,144,916. On average, Colin trades about 9,135 units every 101 days since 2016. As of 15 August 2023 he still owns at least 81,633 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Mr. Meyer stock trades at the bottom of the page.
Colin John Meyer M.D. serves as Executive Vice President, Chief Research and Development Officer of the Company. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.
As the Executive Vice President und Chief Research and Development Officer of Reata Pharmaceuticals Inc, the total compensation of Colin Meyer at Reata Pharmaceuticals Inc is $2,182,780. There are 2 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.
Colin Meyer is 41, he's been the Executive Vice President und Chief Research and Development Officer of Reata Pharmaceuticals Inc since 2020. There are 15 older and no younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.
Colin's mailing address filed with the SEC is 5320 LEGACY DRIVE, , PLANO, TX, 75024.
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy und Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: